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Abstract: Series of multivalent α-l-fucoside containing glycoclusters and variously decorated
l-fucosides were synthesized to find potential inhibitors of fucose-specific lectins and study
the structure-binding affinity relationships. Tri- and tetravalent fucoclusters were built using
copper-mediated azide-alkyne click chemistry. Series of fucoside monomers and dimers
were synthesized using various methods, namely glycosylation, an azide-alkyne click reaction,
photoinduced thiol-en addition, and sulfation. The interactions between compounds with six
fucolectins of bacterial or fungal origin were tested using a hemagglutination inhibition assay. As a
result, a tetravalent, α-l-fucose presenting glycocluster showed to be a ligand that was orders
of magnitude better than a simple monosaccharide for tested lectins in most cases, which can
nominate it as a universal ligand for studied lectins. This compound was also able to inhibit the
adhesion of Pseudomonas aeruginosa cells to human epithelial bronchial cells. A trivalent fucocluster
with a protected amine functional group also seems to be a promising candidate for designing
glycoconjugates and chimeras.
Keywords: l-fucosides; multivalency; lectins; glycoclusters; hemagglutination; cystic fibrosis
1. Introduction
Lectins are specific carbohydrate-binding proteins of a non-immune origin. A common role of
these proteins is their involvement in recognition and adhesion processes between pathogens and
hosts. For example, the chronic infection and colonization of lungs by opportunistic microorganisms is
the main cause of mortality among people suffering from cystic fibrosis (CF) [1]. It was demonstrated
that major changes in CF glycosylation are represented by increased fucosylation and decreased
sialylation [2]. Therefore, lectins from the pathogens could be important virulence factors also
representing a suitable therapeutic target [3]. Three of the most widespread pathogens associated with
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cystic fibrosis—Pseudomonas aeruginosa, Burkholderia cenocepacia, and Aspergillus fumigatus—produce
fucose-specific lectins considered to be involved in pathogenesis. The PA-IIL lectin (LecB) from the
Gram-negative bacterium P. aeruginosa is involved in the adhesion of the bacterium to the host cells via
interactions with host glycoconjugates and in the formation of biofilm [4]. PA-IIL was also shown to
block epithelial cells’ ciliary beating [5]. The BC2L-C lectin from the bacterium B. cenocepacia (closely
related to P. aeruginosa) has two distinct domains with unique selectivity [6]. The N-terminal domain is
a TNF-α-like l-fucose binding domain, while the C-terminal part displays selectivity for d-mannose
and l-glycero-d-manno-heptose in a calcium-dependent manner. The N-terminal domain has a
strong pro-inflammatory effect and is expected to bind fucosylated epitopes on human glycolipids [6].
Aspergillus fumigatus lectin AFL from the fungus A. fumigatus stimulates human bronchial cells to
produce IL-8 and is supposed to contribute to the inflammatory response observed upon the exposure
of a patient to A. fumigatus [7]. Although these lectins are all fucose-specific and their supposed
functions are similar, they differ significantly in terms of their structural arrangement and binding
modes (Figure 1). The N-terminal domain of BC2L-C forms a trimer with binding sites located between
neighboring monomers. PA-IIL is a homotetramer with a single binding site per monomer. Two calcium
ions mediate binding of the sugar in each binding site [8]. AFL is a dimer, where each monomer forms
a six-bladed β-propeller with six non-equivalent binding sites all located on the opposite side of the
molecule to the N- and C-termini [9].
In this study, we focused on potential inhibitors of fucose-specific lectins from pathogens associated
with cystic fibrosis mentioned above. To evaluate common rules for their inhibition, we further included
three AFL homologues, known as AAL (Aleuria aurantia lectin), AOL (Aspergillus oryzae lectin), and RSL
(Ralstonia solanacearum lectin), from the AAL lectin family, sharing the same six-bladed β-propeller fold,
but differing in subtle carbohydrate specificities. The involvement of AOL from Aspergillus oryzae in the
allergic responses to the fungus was proposed with the suggested mechanism of AOL binding to fucose
residues of IgE [10]. AAL from the orange peel fungus Aleuria aurantia was the first characterized
representative of this lectin family. Both AOL and AAL form dimers similar to AFL. In contrast to the
AFL dimer interface, which is formed by loops of all six blades and only the N-terminus is involved,
only the loops of blades 6, 1, and 2 come into contact upon dimerization in AAL and both the N-
and C-termini are crucial [7,11]. AAL contains only five binding sites, with the sixth believed to be
inactive [11]. RSL from Ralstonia solanacearum, a dangerous phytopathogen of important agricultural
plants (e.g., potatoes, tomatoes) [12], may be involved in adhesion of the bacteria, possibly via binding
to terminal fucosides of plant xyloglucans [13]. In contrast to the others, RSL forms the six-bladed
β-propeller fold by trimerization, where the monomers present two binding sites each, one formed by
oligomerization and the second in between the blades of the same monomer (Figure 1) [13].
Lectins are usually multivalent proteins frequently displaying an avidity effect resulting in a
significantly increased affinity towards their ligands. Consequently, the multivalent inhibitors with
several carbohydrate moieties attached are generally considered to be among the most efficient
molecules [14]. Several classes of inhibitors were tested against some of the selected lectins. The known
multivalent inhibitors of AFL include cyclopeptide-based hexavalent compounds with a terminal fucose
residue and multivalent compounds based on cyclodextrin or octameric silsesquioxane scaffolds [15,16].
C-hexopyranosyl calix[4]arene conjugates were used as potential multivalent inhibitors of BC2L-C
and AFL [17]. A broad variety of potential monovalent and multivalent inhibitors were designed and
tested against PA-IIL, including C-glycosidic glycomimetics, cinnamide and sulfonamide carbohydrate
derivatives, fucofullerenes, glycopeptide dendrimers, pentavalent pillar[5]arene-based glycoclusters,
perylenediimide-based glycoclusters, and photoswitchable Janus glycodendrimer micelles [18–24].
Fucofullerenes and C-hexopyranosyl calix[4]arene conjugates were examined as potential multivalent
inhibitors of RSL [17–20].
In our current work, we focused on multivalent (tri- and tetravalent) glycoclusters with different
aglycons (spacers) to exploit their avidity effects. Several thio-α/β-l-fucopyranosides were synthesized
to explore the influence of the presence of the anomeric sulfur on the binding, which are more
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stable in vivo due to the resistance to the degradative enzymes. We further aimed to find a common
inhibitor with a reasonable efficiency for all tested lectins from the pathogens associated with cystic
fibrosis. The inhibitory potency of all used inhibitors against selected lectins was determined by a
hemagglutination inhibition assay with microscope detection, whose robustness and applicability have
been demonstrated previously [25,26].
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Figure 1. Structures of selected lectins from pathogenic microorganisms used for the inhibition studies.
(A) AFL dimer in a complex with seleno fucopyranoside (PDB 4AGI). (B) RSL trimer in a complex with
methyl α-l-fucopyranoside (PDB 2BT9). (C) PA-IIL tetramer in a complex with α-l-fucopyranoside
(PDB 1UZV). (D) Trimer of the BC2L-C N-terminal domain in a complex with seleno fucopyranoside
(PDB 2WQ4). Carbohydrates in the binding sites are depicted as sticks. The magenta spheres represent
calcium ions in the binding sites of lectin PA-IIL.
2. Results and Discussion
Tri- and tetravalent α-l-fucose-presenting glycoclusters 1, 2, 3, and 4 were synthesized
previously [26] (Scheme 1). Similarly to our re ent work [26,27], the fucocluster 5 was
synthesized starting from the propargylated NHBoc-Tris scaffold 6 [28] by coupling ith tosylated
O-(2-azidoethyl)-triethylene g ycol [29] using a Cu(I)-catalyzed azide-alkyne cycloaddition r action
(CuAAC) to get tos lated compound 7 (Scheme 2). The tosyl groups of the scaffold were converted int
azido functions using sodium azide, resulting in compound 8, which was also suit ble for a subsequent
click reacti n and was coupled with acetylat d propargyl α-l-f copyranoside 9 [30] t produce the
protected fucoclust r 10 with a 69% yield. Finally, protecting groups were removed by Zemplén
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deacetylation to get 5, containing a protected NH-group, which is suitable for further conjugation to
synthesize, e.g., chimera compounds and glycoconjugates.
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Scheme 1. Chemical structures of multivalent glycoclusters containing α-L-fucosides. Scheme 1. Chemical structures of multivalent glycoclusters contai i -l-fucosides.
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Other series of already described (11, 2, 13, 14, 17, 18, and 20) or newly synthesized fucosides (15,
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Persulfation of 11 using the SO3.Et3N complex resulted in 15 with an 85% yield, which was
then coupled with O-(2-azidoethyl)triethylene glycol by a click reaction using CuSO4-sodium
ascorbate to get 16 with a 73% yield (Scheme 4). Compound 19 was prepared from 18 and
1,11-diazido-3,6,9-trioxaundecaneglycol by a Cu(I)-catalyzed click reaction with a 53% yield.
Finally, 1,2-cis-α-linked thioglycoside 21 was created in a stereoselective manner by a photoinduced
addition reaction [34,35] between 2-acetoxy-3,4-di-O-acetyl-l-fucal [36] and 2-mercaptoethanol.
The radical-mediated addition provided 24, which was deacetylated by the Zemplén method, resulting
in 21. S-fucoside 22 and thiodisaccharide 23 were prepared by Zemplén deacetylation from their
protected forms 25 and 26 [34], respectively.
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The ability of glycoclusters and l-fuc i i it selected lectins was d termined by a
hemagglutination i hibition ass y with micros ope detection (see Table 1 and Figure 2). The inhibitory
act vity of the tested compounds was semi-quantitatively evaluated by comparison with the standard
(l-fucose). Compounds 15 and 16 were either not able to inhibit any lecti or only very w akly.
Although the binding modes of the AAL family, PA-IIL, and BC2L-C differ, the persulfated compounds
were not functional inhibitors for any of these proteins, probably due to the steric hindrances and/or
requirements of free OH groups for the binding. Compound 17 (thio analogue of l-fucose) was
a slightly better inhibitor of PA-IIL, probably due to its small size, but in general, it performed
poorly. Lectin BC2L-C was not able to recognize 17 at all. Considering β-thio-l-fucopyranosides,
compounds 18 and 19 were generally weak inhibitors with a potency lower than or similar to free
l-fucose. The divalent compound 20 was also not an efficient inhibitor of any lectin, confirming the
known fact that the simple effect of increasing the number of fucose units is not sufficient for the
inhibition [37]. The α-thio-l-fucopyranosides (21, 22, and 23) were generally better inhibitors than
l-fucose for all lectins. It indicated that the weaker binding of 17, 18, and 19 was most likely caused by
the β configuration and not by the presence of sulfur itself. Therefore, the thioglycosides could be
potentially used in the inhibitors to achieve a higher stability towards glycoside hydrolase enzymes.
The derivatization of α-l-fucopyranose with different aglycons did not interfere with the inhibitory
ability of the tested compounds. The α-O-l-fucopyranosides (11, 12, 13, and 14) were equal or better
inhibitors than l-fucose for all lectins. The used linkers are therefore suitable for usage in multivalent
α-l-fucoside-containing glycoclusters. Compounds 12 and 14 were surprisingly very efficient inhibitors
of RSL, with a potency of 32 and 128, respectively. This effect was not observed for any other tested
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lectin, even though AFL, AAL, and AOL are close homologues of RSL. However, RSL differs from
other members of the AAL family by displaying a higher affinity to l-fucose. Compound 12 can
probably form additional interactions with RSL via its side-chain and the divalent nature of 14 could
be enough to exploit the avidity effect of RSL. Considering the multivalent α-l-fucoside-containing
glycoclusters, they proved to be efficient inhibitors of lectins from the AAL family. The best inhibitor
for all lectins was 2, the tetravalent compound with longer tetraethylene-glycol spacers. The length
of the spacers appeared to be more crucial than the number of branches or their topology. For the
majority of the AAL family lectins, the compounds 1, 2, and 5 (longer spacers) worked better than
compounds 3 and 4 (shorter spacers). The exception to this observation was again for RSL, where
5 represented the least preferred multivalent inhibitor. Considering PA-IIL, compound 2 was also
the best inhibitor, even though the binding mode of PA-IIL significantly differs from that of the AAL
family. However, the increment of inhibitory potency of multivalent inhibitors compared to the
monovalent compounds was lower than for the AAL family. Taking into account the simple effect
of the increased concentration of fucose units in the multivalent compound (β, potency/valency),
2 only showed a two times better inhibitory potency than the majority of monovalent compounds
(Table 1). 2 was also the best inhibitor of BC2L-C, but its efficiency was even lower. Generally, in the
case of BC2L-C, the multivalent compounds used in this study did not display a significantly higher
inhibitory potency than monovalent compounds when comparing their β factors. These data may
suggest that BC2L-C does not employ a strong avidity effect during interaction. However, as previously
tested C-hexopyranosyl calix[4]arene-based inhibitors displayed up to a 256-fold increase in inhibitory
potency compared to monovalent l-fucose [17], the currently used multivalent inhibitors may be simply
unable to bind to several binding sites simultaneously and further optimization will be necessary.
Nevertheless, the tetravalent α-O-glycoside 2 with terminal l-fucose with longer spacers surprisingly
proved to be the best inhibitor of all lectins used in this study. This universality could be attributed
to its flexibility and the sufficient length of the spacers. Although the rigid spacers or scaffolds are
generally considered to be more effective for the binding due to the stabilization of optimized sugar
conformations and/or due to the lower entropic cost during interaction [37,38], flexible linkers are
probably more suitable for the non-specialized inhibition of lectins with different binding modes.
As Pseudomonas aeruginosa is the most common pathogen associated with cystic fibrosis and
involvement of its lectin PA-IIL (LecB) in pathogenesis is continually studied [5,39,40], the inhibitory
potential of compound 2 was further evaluated using an ex vivo bacterial adhesion assay. P. aeruginosa
strain 1763 isolated from a cystic fibrosis patient was incubated with epithelial bronchial cells derived
from a cystic fibrosis patient (CuFi-1) in the presence or absence of compound 2. Ten concentrations of
this inhibitor were tested. Compound 2 had a significant protecting effect against P. aeruginosa adhesion
(see Figure 3). Compared to an untreated control, the inhibitor was able to reduce bacterial adhesion to
∼30% when used in the most effective concentration (0.25 mM). Paradoxically, the inhibitory effect
of compound 2 decreased in concentrations above 0.25 mM. This behaviour was attributed to the
cross-linking of bacterial cells by a multivalent inhibitor. The subsequent adhesion of bacterial clusters
to the epithelial cells resulted in an increased fluorescence signal. Cross-linking of bacterial cells
by multivalent carbohydrate-based compounds has been reported previously [17]. In contrast to
the low inhibitory activity against lectin PA-IIL observed in vitro by a hemagglutination inhibition
assay, the results obtained on a cell-cell level indicate that compound 2 has the potential to reduce the
interactions of P. aeruginosa with epithelial cells of humans suffering from cystic fibrosis.
Therefore, it could be used for prophylaxis against the bacterial colonization of bronchial cells,
similarly to, e.g., chicken immunoglobulins [41], because once the airway cells are colonized, any aid
interfering with bacterium adherence is of limited use. As follows from ex vivo experiments with
confluent cell layers and a heavy load of Pseudomonas aeruginosa (8.4 × 106 CFU/well) presented in
this paper, the protective concentration of compound 2 is rather high. It is disputable whether such
a concentration is relevant to in vivo scenarios. However, it should be noted that for cystic fibrosis
patients, it is feasible to reach high doses of medication applied directly to lungs (inhalation). On a
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daily basis, they inhale antibiotics, e.g., 300 mg of tobramycin in 5 mL, two times a day, for 28 days [42].
In another study, patients were treated with the inhalation of 10 mL of 0.1 M fucose/0.1 M galactose
two times a day for 21 days [43]. Of course, a closer look at in vivo conditions is necessary. A mouse
cystic fibrosis model, which is currently being developed [44], is intended to be used.
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Figure 2. Influence of l-fucose, compounds 1, 2, 3, 4, and 5, on hemagglutination caused by lectin PA-IIL.
Used as an illustrative example of the data (images) acquired by a hemagglutination inhibition assay
with microscope detection. The images for lectins AFL, RSL, AAL, AOL, and BC2L-C are included in
the supplementary material. * Standard. Standard experiment was done anew for every used batch of
protein or red blood cells. ** Controls were done anew for every used batch of protein or red blood cells.
Positive control: experiment without any inhibitor. Negative control: experiment without lectin PA-IIL.
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Table 1. Potencies of tested inhibitors against fucose-specific lectins determined by a hemagglutination inhibition assay.
AFL RSL AAL AOL PA-IIL BC2L-C
Inhibitor Valency Potency β# Potency β# Potency β# Potency β# Potency β# Potency β#
l-fucose* 1 1 1 1 1 1 1 1 1 1 1 1 1
Compound 1 3 64 21.3 512 170.7 32 10.7 64 21.3 16 5.3 8 2.7
Compound 2 4 128 32 1024 256 128 32 256 64 32 8 16 4
Compound 3 3 16 5.3 512 170.7 16 5.3 8 2.7 16 5.3 4 1.3
Compound 4 4 16 4 256 64 16 4 8 2 16 4 4 1
Compound 5 3 32 10.7 128 42.7 64 21.3 128 42.7 4 1.3 8 2.7
Compound 11 1 4 4 8 8 4 4 4 4 4 4 1 1
Compound 12 1 8 8 32 32 8 8 8 8 4 4 2 2
Compound 13 1 4 4 8 8 4 4 4 4 4 4 2 2
Compound 14 2 4 2 128 64 8 4 4 2 8 4 2 1
Compound 15 1 0.125 0.125 ND - ND - 0.5 0.5 0.5 0.5 ND -
Compound 16 1 0.125 0.125 ND - ND - ND - 0.125 0.125 0.25 0.25
Compound 17 1 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.25 0.25 ND -
Compound 18 1 0.5 0.5 0.5 0.5 1 1 0.5 0.5 0.03125 0.03125 0.5 0.5
Compound 19 1 1 1 2 2 2 2 1 1 0.0625 0.0625 0.5 0.5
Compound 20 2 0.5 0.25 2 1 1 0.5 1 0.5 0.125 0.0625 1 0.5
Compound 21 1 2 2 4 4 2 2 4 4 4 4 4 4
Compound 22 1 2 2 4 4 2 2 2 2 4 4 4 4
Compound 23 2 8 4 8 4 4 2 8 4 4 2 8 4
* Standard # Potency/Valency ND Not detected.
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Figure 3. P. aeruginosa adhesion to human bronchial epithelial cells (CuFi-1) in the presence of compound
2. Monolayers of CuFi-1 cells stained with PKH67 were exposed to suspensions containing P. aeruginosa
stained with PKH26 and compound 2 (grey bars) or PBS (Phosphate Buffered Saline) as a control
(black bar). After 2-h incubation, non-adhered bacteria were removed by washing and the relative
fluorescence of adhered bacteria and epithelial cells was quantified using Tecan Infinite M200 Pro.
Results are expressed as a relative fluorescence ratio of P. aeruginosa/CuFi-1 plotted as a function of
compound 2’s concentration. Plotted data are means ± SD of three independent incubations.
3. Experiment
3.1. General Methods
Optical rotations were measured at room temperature with a Perkin-Elmer 241 automatic
polarimeter. TLC analysis was performed on Kieselgel 60 F254 (Merck, Kenilworth, NJ, USA) silica gel
plates with visualization by immersion in a sulfuric-acid solution (5% in EtOH) followed by heating.
Column chromatography was performed on silica gel 60 (Merck 0.063–0.200 mm), and flash column
chromatography was performed on silica gel 60 (Merck 0.040–0.063 mm). Gel filtration was performed
on Sephadex G-25 resin, using water as the eluent. Organic solutions were dried over MgSO4 and
concentrated under vacuum. The 1H (400 MHz) and 13C NMR (100.28 MHz) spectra were recorded
with a Bruker DRX-400 spectrometer. Chemical shifts are referenced to Me4Si or DSS (0.00 ppm
for 1H) and to solvent signals (CDCl3: 77.00 ppm, CD3OD: 49.15 ppm, DMSO-d6: 39.51 ppm for
13C). MS (MALDI-TOF) analysis was carried out in positive reflectron mode with a BIFLEX III mass
spectrometer (Bruker, Germany) with delayed-ion extraction. The matrix solution was a saturated
solution of 2,5-dihydroxy-benzoic acid (DHB) in N,N-dimethylformamide.
3.2. Synthesis
Compound 8
Et3N (190 µL, 1 equiv./alkyne) and Cu(I)I (2.5 mg, 0.1 equiv./alkyne) were added to a stirred solution of
6 (466 mg, 1.39 mmol) and 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate [29]
(2.34 g, 6.25 mmol, 1.3 equiv./alkyne) in CH3CN (5 mL) under an argon atmosphere and the mixture
was stirred overnight at room temperature. The reaction mixture was evaporated, and the crude
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product was purified by flash column chromatography (CH2Cl2:MeOH 97:3) to give 7 (1.24 g, 63%) as
a yellowish syrup. Subsequently, NaN3 (333 mg, 6 equiv.) was added to a stirred solution of 7 (1.24 g,
0.85 mmol) in DMF (10 mL) under an argon atmosphere and stirred overnight at room temperature.
The reaction mixture was diluted with water (5 mL), stirred for a further 5 min, and evaporated.
The residue was dissolved in CH2Cl2 (300 mL) and extracted with water (2 × 50 mL) and brine
(50 mL), dried over MgSO4, filtered, and evaporated. The crude product was purified by flash
column chromatography (CH2Cl2/MeOH 97:3) to give 8 (557 mg, 61%) as a colorless syrup. Rf = 0.52
(CH2Cl2:MeOH 95:5). 1H NMR (400 MHz, CDCl3) δ 7.70 (s, 3H, 3 × CH triazole), 4.57 (s, 6H), 4.52
(t, J = 5.1 Hz, 6H), 3.87-3.85 (t, J = 5.1 Hz, 6H), 3.72 (s, 6H, 3 × CH2), 3.65–3.60 (m, 28H, 12 × CH2),
3.37–3.35 (m, 4H), 2.88 (d, 2H), 2.30–2.25 (m, 2H) 1.37 (s, 9H, 3 × CH3). 13C NMR (101 MHz, CDCl3)
δ 154.7 (1C, CO), 144.6 (3C, C=CH), 123.6 (3C, C=CH), 70.5 (3C, 3 × CH2), 70.4, 69.9, 69.3 (18C, 18
× CH2 TEG), 69.1, 64.7 (3C, 3 × CH2), 58.3, 50.5, 50.0 (6C, 6 × NCH2 TEG), 28.2 (3C, 3 × CH3 Boc);
MALDI-TOF MS: m/z 1090.46 [M + Na]+ (calcd for C42H73N19O14 1090.55).
Compound 10
Et3N (73 µL, 1 equiv./alkyne) and Cu(I)I (10 mg, 0.1 equiv./alkyne) were added to a stirred solution of 9
(770 mg, 2.34 mmol) and azide 8 (557 mg, 0.52 mmol, 1.3 equiv./alkyne) in CH3CN (5 mL) under an argon
atmosphere and the mixture was stirred overnight at room temperature. The reaction mixture was
evaporated, and the crude product was purified by flash column chromatography (CH2Cl2:MeOH 97:3)
to give 10 (734 mg, 69%) as a colorless syrup. [α]24D -68.18 (c = 0.22, CHCl3), Rf = 0.38 (CH2Cl2:MeOH
95:5). 1H NMR (360 MHz, CDCl3) δ 7.73 (s, 6H, 6 × CH triazole), 5.37-4.10 (m, 15H, 3 × H-1, H-2, H-3,
H-4), 4.82 (d, J = 12.4 Hz, 3H) 4.66 (d, J = 12.4 Hz, 3H), 4.60-4.53 (m, 15H), 4.25-4.19 (m, 3H) 3.89 (t,
J = 5.2 Hz, 14H,), 3.75 (s, 7H), 3.60 (d, J = 4.0 Hz, 20H, CH2), 2.14, 2.04, 1.9 (s, 27H, 9 × CH3,ac), 2.10-2.01
(m, 2H), 1.40 (s, 9H, 3 × CH3,Boc), 1.1 (d, J = 6.4 Hz, 9H, 3 × C-6).13C NMR (91 MHz, CDCl3) δ 196.7 (1C,
COBoc) 170.4, 170.2, 169.8 (9C, 9 × COac), 144.3 (6C, 6 × C=CH triazol) 123.8, (6C, 6 × C=CH triazol)
95.4 (3C, C-1), 70.9, 67.8, 67.7, 64.5 (12C, Cskeleton), 70.3 (18C, 18 × OCH2), 70.2 (3C, 3 × OCH2), 69.2,
64.5, 61.0 (6C, 6 × OCH2), 50.1 (6C, 6 × NCH2 TEG), 28.2 (3C, 3 × CH3,Boc), 20.6, 20.5 (9C, 9 × CH3,ac),
15.7 (3C, 3 × C-6). MALDI-TOF MS: m/z 2075.16 [M + Na]+ (calcd for C87H133N19O38 2074.90).
Compound 5
To the stirred solution of 10 (90 mg, 0.04 mmol) in dry MeOH (1 mL), a catalytic amount of NaOMe was
added (pH ~ 9). The reaction mixture was stirred overnight at room temperature. The reaction mixture
was neutralized with Amberlite IR-120 H+ ion-exchange resin, filtered, and evaporated, and the crude
product was then purified by flash column chromatography (CH3CN:H2O 7:3) to give compound 5
(53 mg, 73%) as a white powder. [α]24D −27.3 (c = 0.22, MeOH), Rf = 0.37 (CH3CN:H2O 7:3). 1H NMR
(360 MHz, D2O) δ 8.03 (s, 3H, 3 × CH), 7.98 (s, 3H, 3 × CH), 4.95 (bs, 2H), 4.84–4.73 (m, 8H), 4.73–4.63
(m, 8H, 3 × CH2), 4.62–4.74 (m, 18H, 3 ×H-2, H-3, H-4, H-5), 3.89 (d, J = 6.4 Hz, 15H), 3.82–3.69 (m, 9H),
3.52 (dt, J = 24.8, 5.0 Hz, 31H), 1.26 (s, 9H, 3 × CH3), 1.07 (d, J = 6.5 Hz, 9H, 3 × C-6). 13C NMR (91 MHz,
D2O) δ 197.2 (1C, COBoc), 143.8 (6C, 6 × Cq triazol), 125.1 (6C, 6 × CH triazol), 98.5 (3C, C-1), 71.7, 69.5,
67.9, 66.7 (12C, C-skeleton), 69.6 (18C, 18 × CH2), 69.4 (3C, 3 × CH2), 68.6 (1C, Cq), 63.4, 60.5 (6C, 6 ×
CH2), 58.3 (1C, Cq), 49.9 (6C, 6 ×NCH2), 27.5 (3C, 3 × CH3,Boc), 15.2 (3C, 3 × C-6). MALDI-TOF MS:
m/z 1696.91 [M + Na]+ (calcd for C69H115N19O29 1696.80).
Compound 15
Propargyl α-l-fucopyranoside 11 [31] (50 mg, 0.25 mmol) was dissolved in dry DMF (3 mL) and
SO3.Et3N (270 mg, 2 equiv./−OH) was then added under argon atmosphere, and it was stirred overnight.
The reaction mixture was neutralized with aqueous solution of NaHCO3 (250 mg, 6 equiv.) and it was
concentrated. The crude product was suspended in MeOH (5 mL) and filtered to remove salts, and was
then purified by gel filtration to give compound 15 (107 mg, 85%) as a colorless syrup. [α]24D −94.6
(c = 0.13, H2O), Rf = 0.56 (CH2Cl2:MeOH:H2O 7:6:1). 1H NMR (360 MHz, D2O) δ 5.39 (d, J = 3.8 Hz,
1H), 4.93 (d, J = 3.1 Hz, 1H), 4.60–4.51 (m, 2H), 4.40–4.24 (m, 3H), 2.93 (t, J = 2.4 Hz, 1H), 1.28 (d,
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J = 6.5 Hz, 3H).13C NMR (91 MHz, D2O) δ 100.9, 96.6, 79.9, 73.4, 72.9, 67.6, 56.6, 16.6. MALDI-TOF MS:
m/z 531.18 [M + Na]+ (calcd for C9H11Na3O14S3 530.89).
Compound 16
Persulfated propargyl fucoside 15 (50 mg, 0.10 mmol) and O-(2-azidoethyl)triethylene glycol (26 mg,
0.4 mmol) were dissolved in THF:H2O = 1:1 (1 mL) and then CuSO4 (4 mg, 0.2 equiv.) and Na-ascorbate
(20 mg, 1.0 equiv.) were added under argon atmosphere and it was stirred for 4 h. The reaction
mixture was concentrated and the crude product was purified by flash column chromatography
(CH2Cl2:MeOH:H2O 7:6:1) and by gel filtration to give compound 16 (54 mg, 73%) as a colorless syrup.
[α]24D −77.0 (c = 0.10, H2O), Rf = 0.32 (CH2Cl2:MeOH:H2O 7:6:1). 1H NMR (400 MHz, D2O) δ 8.16
(d, J = 3.2 Hz, 1H), 5.32 (dd, J = 3.5, 1.5 Hz, 1H), 4.91 (ddq, J = 3.1, 2.4, 0.8 Hz, 1H), 4.87–4.82 (m, 2H),
4.71–4.61 (m, 3H), 4.56–4.49 (m, 1H), 4.19–4.11 (m, 1H), 4.01–3.94 (m, 2H), 3.71 (dd, J = 6.2, 3.0 Hz, 2H),
3.69–3.59 (m, 11H), 1.19 (dd, J = 6.7, 2.9 Hz, 3H). 13C NMR (101 MHz, D2O) δ 144.6, 126.6, 97.5, 79.8,
73.4, 73.0, 72.6, 70.6, 70.6, 70.4, 69.7, 67.2, 61.9, 61.3, 51.1, 16.6. MALDI-TOF MS: m/z 749.95 [M + Na]+
(calcd for C17H28N3Na3O18S3 750.01).
Compound 19
To a stirred solution of 1,11-diazido-3,6,9-trioxaundecaneglycol (293 mg, 1.2 mmol) and alkyne 18
(138 mg, 0.4 mmol) dissolved in CH3CN (5 mL), Et3N (60 µL, 1 equiv.) and Cu(I)I (8 mg, 0.1 equiv.) were
added under argon atmosphere and it was stirred overnight. The reaction mixture was concentrated
and the crude product was purified by flash column chromatography (CH2Cl2/MeOH 95:5) and gel
filtration to give compound 19 (123 mg, 52%) as a colorless syrup. [α]24D +29.1 (c = 0.11, MeOH),
Rf = 0.23 (CH2Cl2/MeOH 95:5). 1H NMR (400 MHz, Methanol-d4) δ 7.77 (s, 1H), 4.50 (t, J = 5.0 Hz, 2H),
4.28 (d, J = 9.5 Hz, 1H), 4.20 (s, 3H), 3.95 (m, 2H), 3.86 (t, J = 5.1 Hz, 2H), 3.65 (dd, J = 16.2, 7.2 Hz, 12H),
3.48 (dd, J = 9.0, 3.4 Hz, 1H), 3.37 (t, J = 5.0 Hz, 1H), 3.33 (s, 2H), 1.28 (d, J = 6.4 Hz, 3H).13C NMR
(101 MHz, Methanol-d4) δ 145.0, 123.4, 84.8, 74.6, 71.3, 70.2, 70.2, 70.1, 70.1, 69.7, 69.1, 68.9, 50.3, 50.0,
22.7, 16.0. MALDI-TOF MS: m/z 485.26 [M + Na]+ (calcd for C17H30N6O7S 485.18).
Compound 21
A catalytic amount of NaOMe (pH ~9) was added to a stirred solution of 24 (122 mg, 0.2 mmol) in dry
MeOH (3 mL) and stirred overnight at room temperature. The reaction mixture was neutralized with
Amberlite IR-120 H+ ion-exchange resin, filtered, and evaporated, and the crude product was then
purified by flash column chromatography (CH2Cl2/MeOH 95:5) and gel filtration to give compound 21
(154 mg, 78%) as a colorless syrup. [α]24D −331.9 (c = 0.16, MeOH), Rf = 0.23 (CH2Cl2/MeOH 95:5).
1H NMR (400 MHz, Methanol-d4) δ 5.36 (d, J = 5.6 Hz, 1H), 4.31 (qd, J = 6.7, 1.1 Hz, 1H), 4.06 (dd,
J = 10.1, 5.6 Hz, 1H), 3.80–3.54 (m, 4H), 2.78 (ddd, J = 13.5, 7.3, 6.2 Hz, 1H), 2.65 (ddd, J = 13.6, 7.3,
6.5 Hz, 1H), 1.25 (d, J = 6.6 Hz, 4H). 13C NMR (101 MHz, Methanol-d4) δ 88.05 (C-1), 73.39, 72.29, 69.47,
68.07 (C-2,3,4,5), 62.67 (-CH2), 33.70 (-SCH2), 16.57 (C-6). MALDI-TOF MS: m/z 247.32 [M + Na]+ (calcd
for C8H16O5S 247.06).
Compound 22
A catalytic amount of NaOMe (pH ~9) was added to a stirred solution of 25 (109 mg, 0.25 mmol) in dry
MeOH (10 mL) and stirred overnight at room temperature. The reaction mixture was neutralized with
Amberlite IR-120 H+ ion-exchange resin, filtered, and evaporated, and the crude product was then
purified by flash column chromatography (CH3CN/H2O 95:5) to give compound 22 (70 mg, 90%) as
white crystals. Mp.: 248–249 ◦C. [α]24D −268.3 (c = 0.06, MeOH), Rf = 0.53 (CH3CN/H2O 9:1). 1H NMR
(360 MHz, Methanol-d4) δ 5.39 (d, J = 5.6 Hz, 1H, H-1), 4.38–4.19 (m, 1H), 4.06 (dd, J = 10.1, 5.6 Hz,
1H), 3.75–3.54 (m, 2H), 3.18–3.03 (m, 2H), 3.05–2.79 (m, 2H), 1.25 (d, J = 6.5 Hz, 3H, CH3). 13C NMR
(91 MHz, Methanol-d4) δ 88.0 (C-1), 73.4, 72.3, 69.4, 68.1 (C-2,3,4,5), 53.2 (-CH2SO3Na), 26.2 (-SCH2),
16.5 (C-6). MALDI-TOF MS: m/z 333.11 [M + Na]+ (calcd for C8H15NaO7S2 333.01).
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Compound 23
A catalytic amount of NaOMe (pH ~9) was added to a stirred solution of 26 (210 mg, 0.36 mmol) in dry
MeOH (10 mL) and stirred overnight at room temperature. The reaction mixture was neutralized with
Amberlite IR-120 H+ ion-exchange resin, filtered, and evaporated, and the crude product was then
purified by flash column chromatography (CH2Cl2/MeOH 7:3) to give compound 23 (107 mg, 90%) as
a white powder. [α]24D −179.3 (c = 0.30, MeOH), Rf = 0.15 (CH2Cl2/MeOH 8:2). 1H NMR (360 MHz,
Methanol-d4) δ 5.60 (d, J = 5.5 Hz, 2H, H-1, H-1′), 4.42 – 4.38 (m, 4H), 4.07 (dd, J = 10.0, 5.5 Hz, 2H),
3.72–3.35 (m, 8H), 1.26 (d, J = 6.4 Hz, 3H), 1.22 (d, J = 6.5 Hz, 3H). 13C NMR (91 MHz, Methanol-d4) δ
88.1, 87.6 (C-1, C-1′), 76.3, 76.1, 73.4, 73.1, 72.4, 71.8, 69.7, 68.9 (C-2,3,4,5,2′,3′,4′,5′), 17.2, 16.6 (C-6,6′).
MALDI-TOF MS: m/z 349.19 [M + Na]+ (calcd for C12H22NaO8S 349.09).
Compound 24
2-Acetoxy-3,4-di-O-acetyl-l-fucal (272 mg, 1.0 mmol) and 2-mercaptoethanol (140 µL, 2 mmol) were
dissolved in toluene:methanol:water = 8:5:1 (5 mL) and 2,2-dimethoxy-2-phenylacetophenone (DPAP,
25 mg, 0.10 mmol) was added. The solution was irradiated with UV-light at room temperature
for 3 × 15 min. Then, the solution was concentrated and the residue was purified using column
chromatography (n-hexane: aceton 9:1) to give compound 24 (122 mg, 35%) as a colorless syrup. [α]24D
−135.9 (c = 0.02, CH3Cl), Rf = 0.50 (n-hexane: aceton 7:3). 1H NMR (400 MHz, CDCl3) δ 5.74 (d,
J = 5.5 Hz, 1H), 5.37–5.13 (m, 3H), 4.59–4.49 (m, 1H), 3.80 (dt, J = 9.0, 4.6 Hz, 2H), 2.94–2.65 (m, 3H),
2.22–2.15 (m, 4H), 2.11 (d, J = 1.0 Hz, 3H), 2.20, 2.11, 2.04 (s, 3 × 3H), 1.20 (d, J = 6.5 Hz, 3H).
MALDI-TOF MS: m/z 373.54 [M + Na]+ (calcd for C14H22O8S 373.09).
3.3. Lectins Production and Purification
Lectins BC2L-C, AFL, PA-IIL (LecB), and RSL in recombinant forms were produced and purified
as previously described [6–8,13]. Briefly, transformed Escherichia coli cells bearing a plasmid for
the particular lectin were cultured in LB (Luria-Bertani) broth medium containing an appropriate
antibiotic at 37 ◦C. When the culture reached an OD600 of ≈ 0.5, cells were induced by isopropyl
1-thio-β-d-galactopyranoside (IPTG) added to a final concentration of 0.5 mM. Cells were incubated
at 30 ◦C for 3 h, harvested by centrifugation, and resuspended in a suitable buffer. Cells were
then disintegrated by sonication and the cytosolic fraction containing soluble lectin was separated
by centrifugation. Lectins were then purified by affinity chromatography on a d-mannose-agarose
column, dialyzedm and further processed according to the previously published procedures [6–8,13].
Freeze-dried lectins were stored at −20 ◦C. Lectins AAL (Vector Laboratories) and AOL (TCI) were
purchased in a freeze-dried form.
3.4. Hemagglutination Inhibition Assay
Lectins AFL, RSL, AAL, and AOL were dissolved in the PBS buffer to the concentration 0.1 mg·mL−1.
Lectins were mixed with carbohydrate inhibitors serially diluted in PBS buffer in a 5 µL:5 µL ratio.
The final (working) concentration of lectins was therefore 0.05 mg·mL−1. A total of 10 µL of 20%
papain-treated, acid-stabilized red blood cells 0+ in PBS buffer was then added, and the mixture was
thoroughly mixed and incubated for 5 min at room temperature. After incubation, the mixture was
mixed again, transferred to a microscope slide, and examined. The examination was conducted using
the Levenhuk D2L NG Digital Microscope (Levenhuk, Tampa, FL, USA). Images were obtained with a
Levenhuk D2L digital camera (Levenhuk, Tampa, FL, USA) using the software ToupView for Windows
(Levenhuk, Tampa, FL, USA). The positive (experiment without an inhibitor) and negative (experiment
without a lectin) control were prepared and processed in the same way using an appropriate volume
of dissolving buffer instead of the omitted components. The minimal inhibitory concentration (MIC)
of the inhibitor able to inhibit hemagglutination was determined and compared with the standard
(l-fucose), and the potency of the inhibitor was calculated (MIC of the standard/MIC of the inhibitor).
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MIC of the standard was determined every time a new batch of lectins or red blood cells were used for
experiments to diminish the biological variability.
The PA-IIL and BC2L-C lectins were dissolved in the buffer containing calcium ions necessary for
their activity (20 mM Tris/HCl, 150 mM NaCl, 5 mM CaCl2, pH 7.5) to the concentration 2.5 mg·mL−1
and 0.2 mg·mL−1, respectively. Lectins were mixed with carbohydrate inhibitors serially diluted in
the Tris buffer in a 5 µL:5 µL ratio. The final (working) concentration of the lectins was therefore
1.25 mg·mL−1 and 0.1 mg·mL−1. A total of 10 µL of 20% papain-treated, acid-stabilized red blood cells
0+ in the Tris buffer was then added, and the mixture was thoroughly mixed and incubated for 5 min
at room temperature. The examination was conducted and evaluated as mentioned above.
The above-mentioned concentrations of all lectins resulted from optimization, i.e., concentrations
enabling the formation of observable hemagglutinates in 5 min at room temperature were used.
3.5. Pseudomonas Aeruginosa Adherence Assay
3.5.1. Cell Labelling
Epithelial CuFi-1 cells (an immortalized epithelial cell line derived from cystic fibrosis human lungs,
ATCC, Poland) were labelled with PKH67 (Fluorescent Cell Linker Kit, Sigma-Aldrich, Taufkirchen,
Germany), a green fluorescent membrane marker, as follows. An aliquot of cell suspension containing
7 × 106 cells was washed with PBS buffer and centrifuged (100× g for 5 min). The cell pellet was
resuspended in 250 µL of Diluent C (Fluorescent Cell Linker Kit, Sigma-Aldrich, Taufkirchen, Germany).
Immediately, an equal volume of 8 µM PKH67 in Diluent C (2 µL of PKH67 in 248 µL of Diluent C)
was added to the cell suspension. After 5 min incubation at room temperature with periodic mixing,
the staining reaction was stopped by adding an equal volume of 1% Fetal Bovine Serum (GibcoTM
Invitrogen, Paisley, UK) in PBS. After 1 min incubation with FBS, the suspension was centrifuged (100×
g for 10 min). Finally, the cells were washed three times with Bronchial Epithelial Cell Growth Basal
Medium (Lonza, Basel, Switzerland), followed by centrifugation (100× g for 5 min).
Pseudomonas aeruginosa strain 1763 (University Hospital Motol, Prague, Czech Republic) was stained
with PKH26 (Fluorescent Cell Linker Kit Sigma-Aldrich, Germany), a red fluorescent membrane marker.
Bacteria were grown in a suspension culture in PS medium (peptone/casein digest) in an Erlenmeyer flask for
14 h. The culture was washed with PBS buffer and centrifuged (13,400× g for 5 min). The pellet containing
1.5 × 109 bacteria was resuspended in 125 µL of Diluent C (Fluorescent Cell Linker Kit, Sigma-Aldrich,
Germany) and an equal volume of 16 µM PKH26 in Diluent C (2 µL of PKH26 in 123 µL of Diluent C)
was added to the bacterial suspension. The bacteria/dye suspension was incubated for 30 min at room
temperature with periodic mixing. The staining was quenched by adding an equal volume of 1% BSA
(Bovine Serum Albumin) (Merck, Germany) in PBS. The suspension was incubated with BSA for 1 min to
allow the binding of excess dye and then centrifuged (15,700× g for 10 min). Bacteria were washed two
times with PBS, followed by centrifugation (13,400× g for 7.5 and 5 min).
3.5.2. Inhibition of Pseudomonas aeruginosa Adhesion on Epithelial Cells
Epithelial cells CuFi-1 stained with PKH67 were seeded at 8.4 × 104 cells/well onto 96-well plates
(CellBIND® 96-well Flat Clear Bottom Black Polystyrene Microplates, Corning Incorporated, Corning,
NY, USA) and incubated for 42–45 h at 37 ◦C, 5% CO2, to form a confluent monolayer and regenerate.
Prior to the assay, wells were washed with PBS. Compound 2 was diluted with PBS to desired
concentrations (2 µM–1 mM). PKH26-stained bacteria P. aeruginosa were added to the diluted inhibitor
solutions. Bacterial suspensions were immediately added to the wells (50 µL/well). The input ratio
was about 100 bacteria per epithelial cell (8.4 × 106 bacteria/well). A suspension without an inhibitor
was used as a control. After 2 h incubation at room temperature, the wells were extensively washed
three times with PBS to remove non-adhered bacteria The fluorescence of adhered P. aeruginosa cells
(Ex 522 nm, Em 569 nm for PKH26) on epithelial cells (Ex 470 nm, Em 505 for PKH67) was quantified
using the spectrofluorometer Tecan Infinite M200 Pro (Tecan Group Ltd., Männedorf, Switzerland).
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Results were expressed as a relative fluorescence ratio of P. aeruginosa/CuFi-1. Three independent
incubations were performed.
4. Conclusions
The binding of a broad number of newly synthesized l-fucosides of varying structures, including
α- and β-linked mono- and multivalent O- and S-fucosides, as well as persulfated fucoside derivatives,
were tested against six lectins of bacterial and fungal origin. The tetravalent, α-l-fucoside-containing
compound with tetraethylene-glycol bridges (2) was shown to be a universal inhibitor of fucose-specific
lectins from pathogens associated with cystic fibrosis, i.e., P. aeruginosa, B. cenocepacia, and A. fumigatus.
This inhibitor was also able to significantly inhibit the adhesion of P. aeruginosa cells to epithelial bronchial
cells derived from a cystic fibrosis patient in an ex vivo bacterial adherence assay. This molecule also
displayed the best inhibitory potency against the RSL lectin from the plant pathogen R. solanacearum,
suggesting that it could be used to prevent wilting infections of plants. All multivalent inhibitors
worked also well against lectins AAL and AOL.
Supplementary Materials: The following are available online: Figure S1: Influence of l-fucose, compounds 1,
2, 3, 4 and 5 on hemagglutination caused by lectin AFL. Figure S2. Influence of l-fucose, compounds 1, 2, 3,
4, 14 and 5 on hemagglutination caused by lectin RSL. Figure S3. Influence of l-fucose, compounds 1, 2, 3, 4
and 5 on hemagglutination caused by lectin AAL. Figure S4. Influence of l-fucose, compounds 1, 2, 3, 4 and
5 on hemagglutination caused by lectin AOL. Figure S5. Influence of l-fucose, compounds 1, 2, 3, 4 and 5 on
hemagglutination caused by lectin BC2L-C.
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